Insights into antibody-drug conjugates bioanalysis and biomeasures in discovery

“The complexity of antibody–drug conjugates creates challenges in the development of bioanalytical and biomeasure methods that are essential for understanding, selection and development of these modalities. We have outlined just a few of the assays that are typically used to understand the disposition of antibody–drug conjugates.”

Antibody–drug conjugate (ADC) therapeutics utilize the specificity of monoclonal antibodies (mAbs) and potency of highly toxic small molecules. ADCs are typically composed of a mAb with a cytotoxin conjugated to it, resulting in a heterogeneous mixture of mAb with various numbers of toxins. Due to this heterogeneity, characterized by the therapeutic drug-to-antibody ratio (DAR), the selection of bioanalytical tools, biomeasure assays and analytes used to understand and develop ADCs can be challenging [1].

Click here for the full article.